Proxy Votes Now

Home › Funds › Virtus Biotech Clinical Trials ETF

Virtus Biotech Clinical Trials ETF (BBC) proxy voting record 2025-2026

Fund family: ETFis Series Trust I · Filed by ETFis Series Trust I (CIK 1559109) · SEC series S000047353

Ticker: BBC (C000148681)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 740 with, 0 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.

No item-level comparison with other ETFis Series Trust I funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 86.4% of this fund’s 740 such votes could be given a sector; the other 101 (13.6%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care62800.0%
Industrials1100.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections4210
Audit-related1290
Say-on-Pay1080
Compensation450
Corporate Governance250
Capital Structure200
Extraordinary Transactions60
Shareholder Rights and Defenses10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Kodiak Sciences Inc.June 2, 2026$2M50
Oruka Therapeutics, Inc.June 2, 2026$2M40
Gossamer Bio, Inc.June 4, 2026$2M40
Xeris Biopharma Holdings, Inc.June 4, 2026$1M40
Erasca, Inc.June 26, 2026$1M40
Relay Therapeutics, Inc.June 9, 2026$1M50
Xencor, Inc.June 16, 2026$1M120
Amylyx Pharmaceuticals, Inc.June 4, 2026$1M40

Search this fund’s votes by company

755 ballot items at 125 meetings in 2025-2026. Download all votes (CSV)

About this fund’s record

In the 2025-2026 proxy season, Virtus Biotech Clinical Trials ETF (BBC) voted at 125 shareholder meetings of 122 companies, on 755 ballot items in all. Where management made a recommendation, the fund followed it on 100.0% of the items and voted against it 0 times.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.